目的:对58例应用Folfox6方案治疗的晚期结直肠癌患者的临床疗效进行分析。方法:将58例晚期直肠癌患者根据初、复治情况分为初治组(22例)及复治组(36例),对比分析Folfox6方案治疗的临床价值。结果:初治组治疗总有效率为59.10%,复治组治疗总有效率为36.12%,两组治疗总有效率比较未见统计学差异(x2=3.212,P=0.073)。同时两组均发生不同程度的药物毒副作用,所有患者药物毒副作用均可耐受,同时两组比较未见统计学差异(x2=0.659,P=0.416)。结论:晚期结直肠癌初治或复治患者应用Folfox6方案均有着良好的治疗效果,同时药物毒副作用比较未见统计学差异。 Objective: To analyze the clinical effect of 58 patients treated with Folfox6 regimen in patients with advanced colorectal cancer. Methods: Fifty-eight patients with advanced rectal cancer were divided into two groups based on primary and re-treatment: initial treatment group (n = 22) and retreatment group (n = 36). The clinical value of Folfox6 regimen was compared. Results: The total effective rate of initial treatment group was 59.10%, and the total effective rate of retreatment group was 36.12%. There was no significant difference between the two groups (χ2 = 3.212, P = 0.073). At the same time, both groups had different degrees of drug side effects, and all patients were tolerant of drug toxicity. There was no significant difference between the two groups (x2 = 0.659, P = 0.416). Conclusions: The Folfox6 regimen in patients with advanced colorectal cancer who have undergone initial re-treatment or re-treatment has a good therapeutic effect, and there is no statistical difference in drug side-effects.